Key facts
- This page summarizes Eric Hedrick's Form 4 filing for EQRx, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Jan 2023, 20:55.
Eric Hedrick - 01 Jan 2023 Form 4 Insider Report for EQRx, Inc.
- Reporting relationship
- Chief Physician Executive
- Issuer ticker
- N/A
- Reported as of
- 01 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jan 2023, 20:55:41 UTC
- Prior SEC filing
- 01 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ William Collins, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Eric Hedrick filed Form 4 for EQRx, Inc. on 04 Jan 2023.
Change
- Previous filing in this sequence was filed on 01 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EQRX
transaction
Derivative
Earn-out Shares
Award
- Transaction value
- Shares
- +543
- Change %
- +0.53%
- Price
- Shares after
- 103,612
- Date
- 01 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 543
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 543 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 380 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 163 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).